PanOptica: Dropping in on VEGF

PanOptica VEGF receptor inhibitor avoids the needle for wet AMD

Most of the next generation of treatments for age-related macular degeneration are focusing on reducing or eliminating intravitreal injections, which are burdensome to patients and present safety risks. PanOptica Inc. believes its PAN-90806, a small molecule selective inhibitor of VEGF receptor, will be among the best approaches because it has a validated mechanism, is formulated as an easy-to-use eyedrop and has high bioavailability at the disease site.

Last week, PanOptica

Read the full 695 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE